This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
CRI's Jill O'Donnell-Tormey, Ph.D., speaks on the "Public-Private Partnerships Between Research Organizations and BioPharma to Accelerate Cancer Immunotherapies" panel on October 2, 2020, at 1 PM ET.
CRI's Jill O'Donnell-Tormey, Ph.D., speaks on the "ESMO Post-Show" webinar on September 22, 2020, at 3 PM ET.
The Focused Ultrasound Foundation (FUSF) hosts a special conversation with Jill O’Donnell-Tormey, Ph.D., CEO of the Cancer Research Institute (CRI), and Jessica Foley, Ph.D., chief scientific officer of FUSF.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "ASCO Preview" webinar on May 27, 2020, at 3 p.m. ET.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investor Panel" on May 27, 2020, at 12 p.m. CT.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investing into Oncology" and "Oncology Modalities Facing Off" panels.
CRI’s Vanessa Lucey, Ph.D., MBA, speaks on the "Landscape and Evolution of the Marketplace" panel on February 27, 2020.
CRI's Vanessa Lucey, Ph.D., discusses the immuno-onocology landscape in this webinar for the biotechnology industry.
On December 4, CRI's Vanessa Hubbard-Lucey, Ph.D., MBA, is giving a talk on "Challenges and opportunities in designing immuno-oncology trials: A non-profit perspective."
CRI's Vanessa Lucey is presenting a poster on our prostate cancer clinical trial in conjunction with our partners.
CRI's Jun Tang, Ph.D., senior manager, CRI Venture Fund and Clinical Accelerator, is presenting the latest update on the PD1/L1 landscape.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This September for Childhood Cancer Awareness Month, we look at how we’re working toward a future immune to childhood cancer.
This September for Blood Cancer Awareness Month, we look at how we’re working toward a future immune to leukemia, lymphoma, and multiple myeloma.